Abstract
Aim: The effect of Majun Falasfa (MF) was studied on the transgenic Drosophila expressing human alpha synuclein panneurally.
Background: MF is a Unani medicine used for enhancing mental power and treating kidney, joint pains and urinary tract diseases. It is also used for phlegmatic diseases. It is also being used in age related dementia and to counter the effects of ageing.
Methods: The equivalents of recommended dose for human were established for 20g of fly food i.e. 0.0014, 0.0028, 0.0042 and 0.0056g per 20g of diet. The PD flies were allowed to feed on it for 24 days before studying its effect on cognitive and oxidative stress parameters. Immuno-histochemistry was also performed to study the effect of MF on human alpha synuclein expression.
Results: The exposure to MF increased the life span and improved the activity of PD flies. MF delayed the loss of climbing ability of PD flies. The exposure of PD flies to MF significantly reduced the oxidative stress and improves the antioxidant enzymes homeostasis compared to unexposed PD flies. The exposure to MF reduces the formation of Lewy bodies as is evident by immunohistochemistry.
Conclusion: MF is potent in reducing the PD (Parkinson’s disease) symptoms being mimicked in the transgenic flies.
Keywords: Majun falasfa, unani, Drosophila, parkinson’s disease, oxidative stress, alpha synuclein.
Graphical Abstract
Current Traditional Medicine
Title:Effect of Polyherbal Drug Majun Falasfa on the Transgenic Drosophila Model of Parkinson’s Disease
Volume: 7 Issue: 5
Author(s): Yasir Hasan Siddique*, Falaq Naz and Mohammad Rashid
Affiliation:
- Drosophila Transgenic Laboratory, Section of Genetics, Department of Zoology, Faculty of Life Sciences, Aligarh Muslim University, Aligarh, 202002, Uttar Pradesh,India
Keywords: Majun falasfa, unani, Drosophila, parkinson’s disease, oxidative stress, alpha synuclein.
Abstract: Aim: The effect of Majun Falasfa (MF) was studied on the transgenic Drosophila expressing human alpha synuclein panneurally.
Background: MF is a Unani medicine used for enhancing mental power and treating kidney, joint pains and urinary tract diseases. It is also used for phlegmatic diseases. It is also being used in age related dementia and to counter the effects of ageing.
Methods: The equivalents of recommended dose for human were established for 20g of fly food i.e. 0.0014, 0.0028, 0.0042 and 0.0056g per 20g of diet. The PD flies were allowed to feed on it for 24 days before studying its effect on cognitive and oxidative stress parameters. Immuno-histochemistry was also performed to study the effect of MF on human alpha synuclein expression.
Results: The exposure to MF increased the life span and improved the activity of PD flies. MF delayed the loss of climbing ability of PD flies. The exposure of PD flies to MF significantly reduced the oxidative stress and improves the antioxidant enzymes homeostasis compared to unexposed PD flies. The exposure to MF reduces the formation of Lewy bodies as is evident by immunohistochemistry.
Conclusion: MF is potent in reducing the PD (Parkinson’s disease) symptoms being mimicked in the transgenic flies.
Export Options
About this article
Cite this article as:
Siddique Hasan Yasir *, Naz Falaq and Rashid Mohammad , Effect of Polyherbal Drug Majun Falasfa on the Transgenic Drosophila Model of Parkinson’s Disease, Current Traditional Medicine 2021; 7 (5) : e281220189535 . https://dx.doi.org/10.2174/2215083807999201228154544
DOI https://dx.doi.org/10.2174/2215083807999201228154544 |
Print ISSN 2215-0838 |
Publisher Name Bentham Science Publisher |
Online ISSN 2215-0846 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glucocorticoids and the Cardiovascular System: State of the Art
Current Pharmaceutical Design Ca2+ Signalling in Damaged Endothelium and Arterial Remodelling: Do Connexin Hemichannels Provide a Suitable Target to Prevent In-stent Restenosis?
Current Drug Therapy Natural and Synthetic Coumarin Derivatives with Anti-Inflammatory / Antioxidant Activities
Current Pharmaceutical Design The Role of Fatty Acids in the Regulation of Cerebral Vascular Function and Neuroprotection in Ischemia
CNS & Neurological Disorders - Drug Targets Inflammation and Cancer: In Medio Stat Nano
Current Medicinal Chemistry Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Reactive Oxygen and Nitrogen Species in the Renal Ischemia/Reperfusion Injury
Current Pharmaceutical Design Role of Nitrosative Stress and Poly(ADP-ribose) Polymerase Activation in Diabetic Vascular Dysfunction
Current Vascular Pharmacology Impact of Immunosuppressive Drugs on the Development of Cardiac Allograft Vasculopathy
Current Vascular Pharmacology Implication of Heat Shock Protein 90 (HSP90) in Tumor Angiogenesis: A Molecular Target for Anti-Angiogenic Therapy?
Current Cancer Drug Targets Role of Vitamin D in Vascular Complications and Vascular Access Outcome in Patients with Chronic Kidney Disease
Current Medicinal Chemistry New Insights into Binding Interfaces of Coagulation Factors V and VIII and their Homologues - Lessons from High Resolution Crystal Structures
Current Protein & Peptide Science Pharmacological Targeting of Neuronal Kv7.2/3 Channels: A Focus on Chemotypes and Receptor Sites
Current Medicinal Chemistry The Role of Heat Shock Protein (HSP) in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Medicinal Chemistry Mechanisms in the Bed Nucleus of the Stria Terminalis Involved in Control of Autonomic and Neuroendocrine Functions: A Review
Current Neuropharmacology EDITORIAL [Hot Topic: Biomarkers in Cardiovascular Disease (Guest Editor: Dimitris Tousoulis)]
Current Medicinal Chemistry Abdominal Aortic Aneurysm: What About Screening?
Current Pharmaceutical Design Mast Cell Chymase and Tryptase as Targets for Cardiovascular and Metabolic Diseases
Current Pharmaceutical Design Asymmetric Dimethylarginine: a Key Player in the Pathophysiology of Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis in Rheumatoid Arthritis?
Current Pharmaceutical Design New Insights into the Intracellular Mechanisms by Which PGI2 Analogues Elicit Vascular Relaxation: Cyclic AMP-Independent, Gs-Protein Mediated-Activation of MaxiK Channel
Current Medicinal Chemistry - Cardiovascular & Hematological Agents